Evidence map›Paper›PMID 35906240›Full record

ArticleNature communications2022

An acquired phosphatidylinositol 4-phosphate transport initiates T-cell deterioration and leukemogenesis.

Wenbin Zhong, Weize Lin, Yingjie Yang, Dan Chen, Xiuye Cao, Mengyang Xu, Guoping Pan, Huanzhao Chen, Jie Zheng, Xiaoqin Feng and 6 more

Abstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Viral oncogenesis in cancer: from mechanisms to therapeutics.Signal transduction and targeted therapy · 2025
    Review
  4. Article
  5. Article
  6. PI4KIIIβ-Mediated Phosphoinositides Metabolism Regulates Function of the VTA Dopaminergic Neurons and Depression-Like Behavior.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024
    Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Wenbin ZhongMOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, 510632, China.
Weize LinMOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, 510632, China.
Yingjie YangMOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, 510632, China.
Dan ChenMOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, 510632, China.
Xiuye CaoMOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, 510632, China.
Mengyang XuMOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, 510632, China.
Guoping PanMOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, 510632, China.
Huanzhao ChenMOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, 510632, China.
Jie ZhengMOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, 510632, China.
Xiaoqin FengHematology and Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Li Hua YangPediatric Hematology Department, Zhujiang Hospital, Southern Medical University, Guangzhou, 510282, China.
Chaofeng LaiMOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, 510632, China.
Vesa M OlkkonenMinerva Foundation Institute for Medical Research, Biomedicum 2U, FI-00290, Helsinki, Finland.ORCID 0000-0001-5553-7997
Jun XuResearch Center for Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China.
Shuzhong CuiAffiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, 510095, China. Cuishuzhong@gzhmu.edu.cn.ORCID 0000-0003-2178-8741
Daoguang YanMOE Key Laboratory of Tumor Molecular Biology, Jinan University, Guangzhou, 510632, China. tydg@jnu.edu.cn.ORCID 0000-0003-4098-6137

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lipid remodeling is crucial for malignant cell transformation and tumorigenesis, but the precise molecular processes involved and direct evidences for these in vivo remain elusive. Here, we report that oxysterol-binding protein (OSBP)-related protein 4 L (ORP4L) is expressed in adult T-cell leukemia (ATL) cells but not normal T-cells. In ORP4L knock-in T-cells, ORP4L dimerizes with OSBP to control the shuttling of OSBP between the Golgi apparatus and the plasma membrane (PM) as an exchanger of phosphatidylinositol 4-phosphate [PI(4)P]/cholesterol. The PI(4)P arriving at the PM via this transport machinery replenishes phosphatidylinositol 4,5-bisphosphate [PI(4,5)P

Indexed as

Phosphatidylinositol 3-KinasesReceptors, SteroidCarcinogenesisHumansPhosphatidylinositol 4,5-DiphosphatePhosphatidylinositol PhosphatesPhosphatidylinositolsT-LymphocytesPhosphatidylinositol 3-KinasesPhosphatidylinositol 4,5-Diphosphatephosphatidylinositol 4-phosphatePhosphatidylinositol PhosphatesPhosphatidylinositolsReceptors, Steroid

Identifiers

PMID35906240
PMCPMC9338045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.